Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

Kayo Sugimoto; Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Haruma Fujioka; Ke Ih Kim; Yasuhito Tanaka; Yoshihiko Yano; Soo Ki Kim; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Takashi Hatae; Hak Hotta; Yoshitake Hayashi; Masatoshi Kudo

doi:10.1159/000355241

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

Kayo Sugimoto, Soo Ryang Kim, Ahmed El-Shamy, Susumu Imoto, Haruma Fujioka, Ke Ih Kim, Yasuhito Tanaka, Yoshihiko Yano, Soo Ki Kim, Yutaka Hasegawa, Aya Fujinami, Mitsuhiro Ohta, Takashi Hatae, Hak Hotta, Yoshitake Hayashi, Masatoshi Kudo

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR - the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) - were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR.

Original language	English
Pages (from-to)	434-439
Number of pages	6
Journal	Digestive Diseases
Volume	31
Issue number	5-6
DOIs	https://doi.org/10.1159/000355241
State	Published - Nov 2013
Externally published	Yes

Keywords

Double-filtration plasmapheresis
Interferon-β
Null virological response
Peginterferon
Relapse
Ribavirin
Sustained virological response

Access to Document

10.1159/000355241

Cite this

Sugimoto, K., Kim, S. R., El-Shamy, A., Imoto, S., Fujioka, H., Kim, K. I., Tanaka, Y., Yano, Y., Kim, S. K., Hasegawa, Y., Fujinami, A., Ohta, M., Hatae, T., Hotta, H., Hayashi, Y., & Kudo, M. (2013). Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy. Digestive Diseases, 31(5-6), 434-439. https://doi.org/10.1159/000355241

@article{fd4e8885f5654f89a363a6fb3d8fc013,

title = "Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy",

abstract = "Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR - the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) - were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR.",

keywords = "Double-filtration plasmapheresis, Interferon-β, Null virological response, Peginterferon, Relapse, Ribavirin, Sustained virological response",

author = "Kayo Sugimoto and Kim, {Soo Ryang} and Ahmed El-Shamy and Susumu Imoto and Haruma Fujioka and Kim, {Ke Ih} and Yasuhito Tanaka and Yoshihiko Yano and Kim, {Soo Ki} and Yutaka Hasegawa and Aya Fujinami and Mitsuhiro Ohta and Takashi Hatae and Hak Hotta and Yoshitake Hayashi and Masatoshi Kudo",

year = "2013",

month = nov,

doi = "10.1159/000355241",

language = "English",

volume = "31",

pages = "434--439",

journal = "Digestive Diseases",

issn = "0257-2753",

publisher = "S. Karger AG",

number = "5-6",

}

Sugimoto, K, Kim, SR, El-Shamy, A, Imoto, S, Fujioka, H, Kim, KI, Tanaka, Y, Yano, Y, Kim, SK, Hasegawa, Y, Fujinami, A, Ohta, M, Hatae, T, Hotta, H, Hayashi, Y & Kudo, M 2013, 'Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy', Digestive Diseases, vol. 31, no. 5-6, pp. 434-439. https://doi.org/10.1159/000355241

TY - JOUR

T1 - Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

AU - Sugimoto, Kayo

AU - Kim, Soo Ryang

AU - El-Shamy, Ahmed

AU - Imoto, Susumu

AU - Fujioka, Haruma

AU - Kim, Ke Ih

AU - Tanaka, Yasuhito

AU - Yano, Yoshihiko

AU - Kim, Soo Ki

AU - Hasegawa, Yutaka

AU - Fujinami, Aya

AU - Ohta, Mitsuhiro

AU - Hatae, Takashi

AU - Hotta, Hak

AU - Hayashi, Yoshitake

AU - Kudo, Masatoshi

PY - 2013/11

Y1 - 2013/11

N2 - Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR - the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) - were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR.

AB - Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR - the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) - were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR.

KW - Double-filtration plasmapheresis

KW - Interferon-β

KW - Null virological response

KW - Peginterferon

KW - Relapse

KW - Ribavirin

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=84890082867&partnerID=8YFLogxK

U2 - 10.1159/000355241

DO - 10.1159/000355241

M3 - Article

C2 - 24281017

AN - SCOPUS:84890082867

SN - 0257-2753

VL - 31

SP - 434

EP - 439

JO - Digestive Diseases

JF - Digestive Diseases

IS - 5-6

ER -

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this